Cholesterol drug misbranded, company pleads guilty
Cholesterol drug misbranded, company pleads guiltyPharma maker pleads guilty that one of its major drugs was misbranded in a federal court case brought by FDA and the US Department of Justice.
Six barriers to prescribing PCSK9 inhibitorsA National Lipid Association survey has interesting findings on the prescription approval process for PCSK9 inhibitors.
FDA advisors favor new cholesterol-lowering drugs that target PCSK9FDA advisory committee okays two monoclonal antibody formulations in two days for treatment of hypercholesterolemia.
Including cost-effectiveness data in formulary reviewIncorporating cost-effectiveness data into a formulary plan helps shift the conversation from cost to value when considering which drugs to include.
FDA drug approvals-January 2015FDA actions in brief, recommendations for approval, fast-track designations.
Investigational ACL inhibitor shows promise in lowering LDL cholesterolACL inhibitor ETC-1002 (Esperion) met its primary end point of greater LDL-cholesterol lowering from baseline with ETC-1002 compared with ezetimibe, according to a study.
Adolescents are eating their way to heart disease
Adolescents are eating their way to heart diseaseThe adolescent diet of fat, salt, and sugar is leading US teenagers on the path to early cardiovascular disease, according to new research from the American Heart Association.